Stebbins K E, Johnson K A, Jeffries T K, Redmond J M, Haut K T, Shabrang S N, Stott W T
Toxicology & Environmental Research and Consulting, The Dow Chemical Company, 1803 Building, Midland, Michigan, 48674, USA.
Regul Toxicol Pharmacol. 2000 Aug;32(1):1-13. doi: 10.1006/rtph.2000.1398.
Fischer 344 rats and B6C3F1 mice were administered 1, 3-dichloropropene (1,3-D) via their diets for up to 2 years, at dose levels of 0, 2.5, 12.5, or 25 mg 1,3-D/kg body wt/day for rats and 0, 2.5, 25, or 50 mg 1,3-D/kg body wt/day for mice. The test material was stabilized in the feed by microencapsulation in a starch/sucrose matrix (80/20%). Rats given 12.5 or 25 mg/kg/day, and mice given 25 or 50 mg/kg/day, had decreased body weights and body weight gains. There were no effects on survival or clinical pathology parameters for rats or mice. Histopathologic effects attributed to treatment in rats consisted of basal cell hyperplasia of the nonglandular mucosa of the stomach in males and females given 12.5 or 25 mg/kg/day for 12 and 24 months and an increased number of hepatocellular adenomas in males given 12.5 or 25 mg/kg/day and females given 25 mg/kg/day for 24 months. The increase in hepatocellular adenomas was statistically identified by pairwise comparison only in males given 25 mg/kg/day. An increased incidence of eosinophilic foci of altered cells in the liver was also noted in all treated groups of rats at 24 months. The latter observation, however, was considered of equivocal toxicological significance because of the common spontaneous occurrence of liver foci in aged Fischer 344 rats. The only histologic change attributed to treatment in mice was decreased size of hepatocytes in males given 50 mg/kg/day for 12 months. The decreased size of hepatocytes was consistent with decreased cytoplasmic glycogen content and corresponded to decreased liver weights. This effect was not present at 24 months. There was no oncogenic response observed in mice. The low-dose level of 2.5 mg/kg/day was interpreted as the no-observed-adverse-effect level (NOAEL) for systemic chronic toxicity of 1,3-D in the Fischer 344 rat. The no-observed-effect level (NOEL) for chronic systemic toxicity was 2.5 mg/kg/day in the B6C3F1 mouse.
将Fischer 344大鼠和B6C3F1小鼠通过饮食给予1,3 - 二氯丙烯(1,3 - D),持续2年,大鼠的剂量水平为0、2.5、12.5或25毫克1,3 - D/千克体重/天,小鼠的剂量水平为0、2.5、25或50毫克1,3 - D/千克体重/天。测试材料通过微囊化在淀粉/蔗糖基质(80/20%)中稳定在饲料中。给予12.5或25毫克/千克/天的大鼠以及给予25或50毫克/千克/天的小鼠体重和体重增加减少。对大鼠或小鼠的存活率或临床病理学参数没有影响。在大鼠中,归因于处理的组织病理学效应包括给予12.5或25毫克/千克/天、持续12和24个月的雄性和雌性大鼠胃非腺性黏膜的基底细胞增生,以及给予12.5或25毫克/千克/天的雄性大鼠和给予25毫克/千克/天、持续24个月的雌性大鼠肝细胞腺瘤数量增加。肝细胞腺瘤的增加仅在给予25毫克/千克/天的雄性大鼠中通过成对比较在统计学上得到确认。在24个月时,所有处理组的大鼠肝脏中嗜酸性细胞改变灶的发生率也有所增加。然而,由于老年Fischer 344大鼠肝脏病灶常见的自发发生,后一观察结果被认为毒理学意义不明确。在小鼠中,归因于处理的唯一组织学变化是给予50毫克/千克/天、持续12个月的雄性小鼠肝细胞大小减小。肝细胞大小减小与细胞质糖原含量降低一致,并与肝脏重量减轻相对应。这种效应在24个月时不存在。在小鼠中未观察到致癌反应。2.5毫克/千克/天的低剂量水平被解释为1,3 - D对Fischer 344大鼠全身慢性毒性的未观察到有害作用水平(NOAEL)。B6C3F1小鼠慢性全身毒性的未观察到作用水平(NOEL)为2.5毫克/千克/天。